Does Chemo Cause High Blood Pressure?

Several widely used cancer therapies do raise blood pressure, and in some cases significantly. The drugs most closely tied to this side effect are not always the traditional chemotherapy agents people picture. Targeted therapies that block blood-vessel growth, certain proteasome inhibitors, and platinum-based drugs are among the strongest offenders, while supportive medications given alongside chemo can quietly push readings higher too. A scientific statement from the American Heart Association identifies hypertension as one of the most common side effects of modern cancer treatment, particularly with drugs that target blood-vessel signaling pathways.

Which Cancer Drugs Are Most Likely to Raise Blood Pressure

Not all chemotherapy drugs carry the same risk. The biggest culprits fall into a few distinct categories, each with a different profile of how often and how severely they affect blood pressure.

Drugs that block vascular endothelial growth factor, or VEGF, are the most notorious group. Bevacizumab, sorafenib, and similar agents designed to starve tumors of their blood supply reliably push blood pressure upward. In animal studies, sorafenib-treated subjects developed blood pressure readings that climbed steadily over weeks, reaching dangerously elevated levels by the end of treatment.¹ In patients, the rise is common enough that oncologists expect it and monitor for it routinely.

Proteasome inhibitors used for multiple myeloma are another significant source. Carfilzomib, a second-generation drug in this class, causes hypertension in roughly one in eight patients, making it the most frequent cardiovascular side effect of the drug.² About a third of patients on carfilzomib experience some kind of cardiovascular adverse event, and the vast majority of those involve uncontrolled blood pressure.³

Platinum-based drugs like cisplatin, a backbone of treatment for testicular cancer and other solid tumors, cause blood pressure problems that can show up during treatment or years afterward. These compounds linger in the body for an extraordinarily long time: traces of platinum have been measured in the bloodstream more than a decade after the last dose, and higher long-term platinum concentrations correlate with higher rates of hypertension.⁴

Certain tyrosine kinase inhibitors used for chronic myeloid leukemia also affect blood pressure unevenly. In one study, about a third of patients on these drugs had uncontrolled blood pressure when measured with 24-hour monitoring, and nilotinib showed worse blood pressure control than the alternatives imatinib and dasatinib.⁵

How These Drugs Push Blood Pressure Up

The mechanisms vary by drug class, but they converge on a few shared pathways. The American Heart Association’s scientific statement identifies reduced nitric oxide production, oxidative stress, endothelial dysfunction, and shrinkage of the body’s smallest blood vessels as key contributors.⁶

For VEGF-blocking drugs, the core issue is that the signaling molecule they suppress does more than feed tumors. VEGF also helps maintain nitric oxide production in normal blood vessels. When that signal gets blocked, blood vessels lose their ability to relax properly, and the tiniest vessels in the body start to thin out and disappear, a process called microvascular rarefaction. Because those small vessels are largely responsible for controlling resistance to blood flow, losing them drives pressure up.⁷ Researchers studying the skin’s microcirculation in patients on bevacizumab have directly demonstrated that the drug impairs the small-vessel responses that normally keep blood pressure in check.

Carfilzomib appears to work through a different route entirely. Research points to disrupted ion channel activity in the kidneys: the drug interferes with the balance of water and salt reabsorption in the collecting ducts, which increases the volume of fluid the heart has to pump and raises pressure from the preload side rather than by constricting vessels.⁸

Cisplatin damages the endothelium, the inner lining of blood vessels, and promotes the production of thromboxane-A2, a molecule that constricts blood vessels and encourages clotting.⁹ Because the drug persists in the body so long, that endothelial damage can continue well beyond the treatment period.

Supportive Medications That Quietly Add to the Problem

Chemotherapy rarely travels alone. The supportive drugs given to manage nausea, inflammation, pain, and immune reactions can independently raise blood pressure, and this contribution often gets overlooked. The AHA scientific statement specifically flags corticosteroids, calcineurin inhibitors, and nonsteroidal anti-inflammatory drugs as adjunctive therapies that further increase blood pressure during cancer treatment.⁶

Dexamethasone, a steroid routinely given before and after highly emetogenic chemotherapy to prevent vomiting, illustrates the point. In one study following patients who received dexamethasone as an anti-nausea treatment alongside high-emetic-risk chemo, about a quarter of them developed new hypertension within six months.¹⁰ That is a striking rate for a drug most patients think of as “just something for nausea.” Steroids promote fluid retention and metabolic changes that push blood pressure upward, and when layered on top of chemo drugs that already stress the cardiovascular system, the combined effect can be substantial.

Hormone therapies for prostate and breast cancer deserve mention here too, even though they are not chemotherapy in the traditional sense. Androgen deprivation therapy for prostate cancer roughly doubles the rate of new-onset hypertension compared to untreated controls, with the strongest effect seen in patients on combined androgen blockade.¹¹ For breast cancer, aromatase inhibitors may contribute to elevated blood pressure through estrogen depletion and resulting endothelial changes, though the evidence here is less settled.¹²

Pain itself can temporarily raise blood pressure readings, as can anxiety, sleep disruption, and the general physiological stress of being treated for cancer. Accurate blood pressure measurement during cancer treatment requires awareness of these confounders, since a reading taken during acute pain or shortly after a steroid dose may not reflect a patient’s true baseline.¹³

Immune Checkpoint Inhibitors and Blood Pressure

A newer class of cancer drugs, immune checkpoint inhibitors, was not initially thought of as a major blood pressure concern. These drugs work by releasing the brakes on the immune system rather than targeting blood vessels directly. But accumulating evidence suggests they do raise the risk. In a large comparative study, patients treated with immune checkpoint inhibitors developed new hypertension at a rate of about 13%, compared to roughly 10% in cancer patients not receiving these drugs, a statistically meaningful difference.¹⁴ The gap may seem modest in percentage terms, but given how widely checkpoint inhibitors are now used across dozens of cancer types, the absolute number of patients affected is large. The mechanism is still being worked out, though immune-mediated inflammation of blood vessel walls is one plausible contributor.

Long-Term Blood Pressure Effects After Treatment Ends

For many patients, the reassuring news is that cancer-therapy-induced hypertension is usually reversible after treatment stops.⁶ Blood pressure that spiked during a course of bevacizumab, for instance, often drifts back down once the drug is cleared.

But “usually reversible” is not “always reversible,” and platinum-based chemotherapy is the starkest exception. Testicular cancer survivors treated with cisplatin-based regimens showed significantly stiffer arteries more than 20 years after their treatment compared to both healthy controls and testicular cancer survivors who had surgery alone. The rate at which their arteries stiffened with age was also steeper, suggesting the drug accelerated vascular aging rather than just causing a temporary spike.¹⁵

Childhood cancer survivors face an especially long tail of cardiovascular risk. Using data from large survivorship cohorts, researchers have found that about 15% of childhood cancer survivors self-reported hypertension by their mid-thirties, and the number climbed to roughly 40% by age 50. In a cohort that used in-person blood pressure measurements instead of self-reports, the prevalence exceeded 70% by age 50.¹⁶ Anthracyclines, a class of traditional chemotherapy drugs used heavily in pediatric cancers, are considered a major contributor to this pattern.¹⁷ These survivors were treated as children, often before they had any cardiovascular risk factors at all, and yet they develop hypertension at rates far exceeding age-matched peers decades later.

When Rising Blood Pressure Might Actually Be a Good Sign

One of the more counterintuitive findings in this area involves bevacizumab, the VEGF-targeting drug. Because the drug raises blood pressure by shutting down the same vessel-growth pathway it uses to fight tumors, some researchers have asked whether the blood pressure rise itself signals that the drug is working. There is evidence it does. In patients with metastatic colorectal cancer, those who developed hypertension during bevacizumab treatment had significantly better progression-free and overall survival than those who did not.¹⁸ This does not mean high blood pressure is desirable, but it suggests the side effect and the anti-tumor effect share a biological root. For patients who develop hypertension on bevacizumab and wonder whether it is worth tolerating, this finding offers some context: the blood pressure response may reflect that the drug is doing its job against the cancer.

Who Is Most Vulnerable

Pre-existing cardiovascular health matters enormously. Patients who already have elevated blood pressure, thickened heart walls, or stiffened arteries before starting treatment are more likely to develop cardiovascular problems during therapy. In the carfilzomib studies, patients who went on to have cardiovascular adverse events had measurably higher baseline blood pressure, greater left ventricular mass, and stiffer arteries before they ever received a dose of the drug.³ This has practical implications: getting blood pressure well controlled before starting cancer therapy reduces the risk that it will spin out of control during treatment.

There is also a genetic component. A genome-wide study of over a thousand patients treated with bevacizumab identified a specific genetic variant in a gene called KCNAB1 that helped predict which patients would develop drug-induced hypertension. The finding was validated in an independent group of patients, suggesting it could eventually become a clinical tool for screening.¹⁹ For now, this remains a research finding rather than something your oncologist will order, but it reinforces that the blood pressure response to cancer therapy is not random: some people are biologically primed to react more strongly.

Managing Blood Pressure During Cancer Treatment

Despite how common cancer-therapy-induced hypertension is, there are no dedicated clinical trials establishing a best-in-class treatment strategy specifically for this population. The AHA statement notes that management currently follows the same guidelines used for hypertension in the general population, with some cancer-specific considerations layered on top.⁶ ACE inhibitors and calcium channel blockers are commonly chosen first-line agents, in part because they do not interfere with most cancer therapies and because some animal data suggest ACE inhibitors may offer additional vascular protection.

Getting a thorough cardiovascular assessment before starting a potentially hypertensive cancer therapy is considered essential. That means not just a single blood pressure check but attention to overall cardiovascular risk factors like cholesterol, kidney function, and any existing heart damage. The stakes are real: cancer-therapy-induced hypertension is described as “dose limiting” in the AHA statement, meaning it can force oncologists to reduce doses or pause treatment, which directly affects how well the cancer itself is managed.

One important caveat for the period after treatment ends: when a drug that was raising blood pressure is discontinued, the antihypertensive medications that were added to control it may suddenly be too strong. The AHA statement specifically warns about rebound low blood pressure after cancer therapy stops, a risk that requires tapering or discontinuing blood pressure medications under medical supervision rather than just continuing them indefinitely.

Kidney Damage as a Hidden Driver

Some of the blood pressure effects of cancer therapy trace back to kidney injury that does not always announce itself with obvious symptoms. In sorafenib-treated animals, extended treatment produced not only sustained hypertension but also progressive kidney damage, including scarring, injury to the filtration units, and loss of nephrin, a protein critical for normal kidney filtering function.¹ Carfilzomib’s mechanism also runs through the kidneys, disrupting how they handle salt and water.⁸ This means that for patients on these drugs, monitoring kidney function alongside blood pressure offers a more complete picture than tracking pressure alone. Catching kidney stress early can sometimes allow dose adjustments before blood pressure becomes unmanageable, and it flags patients who may need closer cardiovascular follow-up long after their cancer treatment is over.